BalanceBio

BalanceBio is a clinical-stage biotechnology company focused on developing novel therapies for neurological disorders, specifically targeting cognitive impairment. The company's lead candidate, BT-001, is a proprietary low-dose formulation of pentylenetetrazol (PTZ) that acts as a GABA-A receptor antagonist to normalize the balance between inhibitory and excitatory signaling in the brain. BalanceBio is primarily advancing BT-001 through Phase 2 clinical trials for the treatment of cognitive deficits associated with Down syndrome. Additionally, the company is exploring the application of its therapeutic approach in other conditions such as Alzheimer's disease. By leveraging insights into GABAergic signaling, BalanceBio aims to provide life-changing treatments for patients with significant unmet medical needs.